A phase 1/2 trial of CR-001 in advanced solid tumours, run by Crescent Biopharma, Inc., now recruiting.
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT07335497 by Crescent Biopharma, Inc., with 290 participants planned, started 2026-02-17 and due to reach its primary completion in 2029-02. Interventions recorded: CR-001.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.